ArticleFrontiers in oncology2026

Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer.

Frontiers Editorial OfficePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.